S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Your Money is Not Safe (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Your Money is Not Safe (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Your Money is Not Safe (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Your Money is Not Safe (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:ORPH

Orphazyme A/S (ORPH) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free ORPH Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.57
▼
$2.21
52-Week Range
N/A
Volume
941,400 shs
Average Volume
1.37 million shs
Market Capitalization
$30.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ORPH stock logo

About Orphazyme A/S Stock (NASDAQ:ORPH)

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

ORPH Stock News Headlines

April 18, 2024 | nbcnews.com
Inside Gen Alpha’s controversial obsession with skincare
April 13, 2024 | msn.com
It’s the first drug shown to slow Alzheimer’s. Why is is it off to a slow start?
April 19, 2024 | InvestorPlace (Ad)
You’re invited: Biggest crypto event of 2024
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
April 12, 2024 | msn.com
Lysine Is Important for the Body, and Is Generally a Safe Supplement
April 11, 2024 | markets.businessinsider.com
Zevra Therapeutics: Strong Buy on Strategic Financing and Promising Drug Portfolio
April 8, 2024 | msn.com
From fungi to feast: The rise of Mycoprotein as a sustainable protein solution
April 3, 2024 | msn.com
Ask A Doctor: What Diseases Cause Encephalopathy?
April 1, 2024 | msn.com
Chemists discover a key protein in how lysosomes work
April 19, 2024 | InvestorPlace (Ad)
You’re invited: Biggest crypto event of 2024
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
March 28, 2024 | msn.com
Orry refuses to shake woman’s hand citing ‘germs,’ threatens legal action after her video
March 28, 2024 | msn.com
A Guide To Pokémon's Poison Type
March 18, 2024 | msn.com
Understanding what causes trastuzumab's cardiotoxicity
March 16, 2024 | msn.com
How a brash, red-haired orphan from P.E.I. continues to be a worldwide sensation
March 14, 2024 | msn.com
Sindica - A Novel, Patented Post-emergence Herbicide for Sugarcane from Atul
March 12, 2024 | msn.com
Sharing a Drink With Orphaned Opossum Babies
March 12, 2024 | msn.com
Zevra adds bull at William Blair despite delay in arimoclomol decision
March 11, 2024 | msn.com
'Why haven't they shown us the original photo?' Anti-monarchist FUMES over Kate's apology - ‘Doesn't explain anything’
March 10, 2024 | nytimes.com
A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market
March 5, 2024 | msn.com
Alnylam’s experimental drug for high blood pressure yields encouraging results
March 4, 2024 | marketwatch.com
FDA Extends Review of Zevra's Arimoclomol by Three Months
February 23, 2024 | msn.com
Ladybug scents offer a more ecologically friendly way to protect crops
February 23, 2024 | msn.com
Gen Alpha have a say on which names they consider to be 'old'
February 23, 2024 | yahoo.com
One Piece: Is S-Hawk the Strongest Seraphim in the Series?
February 22, 2024 | msn.com
What Is The History Of Phenylketonuria? A Review By Doctors
January 31, 2024 | msn.com
New Horizons in Chemical Biology: A Novel Approach to Synthesize Dibenzothiophene S-Oxides
January 31, 2024 | msn.com
Chemical biology: A novel approach to synthesize dibenzothiophene s-oxides
December 5, 2023 | markets.businessinsider.com
Levi & Korsinsky, LLP Notifies Shareholders of Orphazyme (ORPH) an Upcoming Claims Deadline in a Class Action Settlement
See More Headlines
Receive ORPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orphazyme A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORPH
CUSIP
N/A
CIK
1764791
Web
www.orphazyme.com
Phone
45-2898-9055
Fax
N/A
Employees
141
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.14
Current Ratio
1.80
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.74 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
35,312,000
Free Float
N/A
Market Cap
$30.72 million
Optionable
Not Optionable
Beta
1.68
7 Stocks to Own Before the 2024 Election Cover
7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Anders Fink Vadsholt M.B.A. (Age 52)
    M.Sc., MBA, Chief Financial Officer
    Comp: $924.24k
  • Mr. Christophe Bourdon M.B.A. (Age 51)
    Chief Exec. Officer
  • Dr. Thomas Kirkegaard Jensen Ph.D. (Age 44)
    Co-Founder & Chief Scientific Officer
  • Ms. Molly Carey Poarch
    Head of Global Communications
  • Dr. Thomas Blaettler (Age 54)
    Chief Medical Officer
  • Ms. Molly Painter (Age 45)
    Pres of Orphazyme US, Inc.

Key Competitors

View All Competitors

ORPH Stock Analysis - Frequently Asked Questions

When did Orphazyme A/S IPO?

Orphazyme A/S (ORPH) raised $100 million in an initial public offering on Tuesday, September 29th 2020. The company issued 7,600,000 shares at a price of $13.13 per share. BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Danske Markets was co-manager.

This page (NASDAQ:ORPH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research